ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer

December 28, 2012

NCCTG Plans To Conduct Phase II Study Of Brostallicin Plus Cisplatin For mTNBC

April 30, 2010

Hait To Take Office As AACR President, DuBois Is President-Elect.

March 30, 2007

In Brief: Hatch Restores NCI Budget Bypass Authority In His Bill Renewing National Cancer Act

April 23, 1982

New HIP Analysis Supports Mammography Screening Ages 40-49

September 23, 1988

Cancer Organizations Continue Reform Lobbying: Target Issue Are Off-Label Drugs, Clinical Trials

March 26, 1993